Patents by Inventor Leah Frye

Leah Frye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20230365584
    Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for inhibiting kinase activity, and for treating cancer.
    Type: Application
    Filed: September 8, 2021
    Publication date: November 16, 2023
    Inventors: Xianhai HUANG, Sayan MONDAL, Phani GHANAKOTA, Nicholas BOYLES, Leah FRYE, Adam LEVINSON, Jeremy Robert GREENWOOD, Pieter BOS, Sathesh BHAT, Aleksey GERASYUTO, Haifeng TANG
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE
    Publication number: 20230348424
    Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for inhibiting certain protein- protein interactions, and for treating cancer.
    Type: Application
    Filed: February 3, 2023
    Publication date: November 2, 2023
    Inventors: Adam Marc Levinson, Evelyne Houang, Abba Elias Leffler, Andrew Placzek, Anatoly Ruvinsky, Jeremy Robert Greenwood, Zef Konst, Leah Frye
  • CYCLIC COMPOUNDS AND METHODS OF USING SAME
    Publication number: 20230101747
    Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for inhibiting kinase activity, and for treating cancer.
    Type: Application
    Filed: December 3, 2020
    Publication date: March 30, 2023
    Inventors: Xianhai Huang, Sayan Mondal, Phani Ghanakota, Nicholas Boyles, Leah Frye, Aleksey Gerasyuto, Jeremy Robert Greenwood, Haifeng Tang, Adam Marc Levinson
  • Neuronal pain pathway modulators
    Patent number: 9402826
    Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: August 2, 2016
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
  • NEURONAL PAIN PATHWAY MODULATORS
    Publication number: 20150126576
    Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.
    Type: Application
    Filed: September 29, 2014
    Publication date: May 7, 2015
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
  • Neuronal pain pathway modulators
    Patent number: 8846742
    Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: September 30, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
  • Neuronal Pain Pathway Modulators
    Publication number: 20080176920
    Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.
    Type: Application
    Filed: February 14, 2007
    Publication date: July 24, 2008
    Inventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20050032772
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: September 9, 2004
    Publication date: February 10, 2005
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Emmanuel, Leah Frye, Eugene Hickey, Weimin Liu, Tina Morwick, Denice Spero, Sanxing Sun, David Thomson, Yancey Ward, Erick Young
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20050032792
    Abstract: Disclosed are cathepsin S ,K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: September 9, 2004
    Publication date: February 10, 2005
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Emmanuel, Leah Frye, Eugene Hickey, Weimin Liu, Tina Morwick, Denice Spero, David Thomson, Yancey Ward, Erick Young